Shire (NASDAQ:SHPGY) recently entered into an agreement with arGEN-X, a Netherlands-based privately-held biopharmaceutical company, to create novel treatments for rare genetic diseases.
As per the terms of the deal, Shire retains an option to license the candidates for exclusive development (preclinical and clinical) and commercialization worldwide. In exchange of this option, arGEN-X will be eligible to receive an upfront technology access fee, research funding, preclinical success payments, … [visit site to read more] or compare Credit Card Rewards and Best Credit Cards
Nasdaq quotes delayed at least 15 minutes, all others at least 20 minutes.
Markets are closed on certain holidays. Stock Market Holiday List
By accessing this page, you agree to the following
Press Release Service provided by PRConnect.
Stock quotes supplied by Telekurs USA
Postage Rates Bots go here